June 30, 2026 · Form 4 insider transaction
Danziger Asaf bought 268 shares of NovoCure Limited at $11.15 per share, a transaction worth $3.0K. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 1 day after the transaction.
The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c).; In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026.